Clinical Presentations and Outcomes of Children in Canada With Recurrent Invasive Pneumococcal Disease From the IMPACT Surveillance Network.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
pubmed:
31
1
2022
medline:
20
4
2022
entrez:
30
1
2022
Statut:
ppublish
Résumé
Invasive pneumococcal disease due to Streptococcus pneumoniae can cause mortality and severe morbidity due to sepsis, meningitis and pneumonia, particularly in young children and the elderly. Recurrent invasive pneumococcal disease is rare yet serious sequelae of invasive pneumococcal disease that is associated with the immunocompromised and leads to a high mortality rate. This retrospective study reviewed recurrent invasive pneumococcal disease cases from the Canadian Immunization Monitoring Program, ACTive (IMPACT) between 1991 and 2019, an active network for surveillance of vaccine-preventable diseases and adverse events following immunization for children ages 0-16 years. Data were collected from 12 pediatric tertiary care hospitals across all 3 eras of public pneumococcal conjugate vaccine implementation in Canada. The survival rate within our cohort of 180 recurrent invasive pneumococcal disease cases was 98.3%. A decrease of 26.4% in recurrent invasive pneumococcal disease due to vaccine serotypes was observed with pneumococcal vaccine introduction. There was also a 69.0% increase in the rate of vaccination in children with preexisting medical conditions compared with their healthy peers. The decrease in recurrent invasive pneumococcal disease due to vaccine-covered serotypes has been offset by an increase of non-vaccine serotypes in this sample of Canadian children.
Sections du résumé
BACKGROUND
Invasive pneumococcal disease due to Streptococcus pneumoniae can cause mortality and severe morbidity due to sepsis, meningitis and pneumonia, particularly in young children and the elderly. Recurrent invasive pneumococcal disease is rare yet serious sequelae of invasive pneumococcal disease that is associated with the immunocompromised and leads to a high mortality rate.
METHOD
This retrospective study reviewed recurrent invasive pneumococcal disease cases from the Canadian Immunization Monitoring Program, ACTive (IMPACT) between 1991 and 2019, an active network for surveillance of vaccine-preventable diseases and adverse events following immunization for children ages 0-16 years. Data were collected from 12 pediatric tertiary care hospitals across all 3 eras of public pneumococcal conjugate vaccine implementation in Canada.
RESULTS
The survival rate within our cohort of 180 recurrent invasive pneumococcal disease cases was 98.3%. A decrease of 26.4% in recurrent invasive pneumococcal disease due to vaccine serotypes was observed with pneumococcal vaccine introduction. There was also a 69.0% increase in the rate of vaccination in children with preexisting medical conditions compared with their healthy peers.
CONCLUSION
The decrease in recurrent invasive pneumococcal disease due to vaccine-covered serotypes has been offset by an increase of non-vaccine serotypes in this sample of Canadian children.
Identifiants
pubmed: 35093996
doi: 10.1097/INF.0000000000003454
pii: 00006454-202204000-00028
pmc: PMC8920017
doi:
Substances chimiques
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e166-e171Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Gaschignard J, Levy C, Chrabieh M, et al. Invasive pneumococcal disease in children can reveal a primary immunodeficiency. Clin Infect Dis. 2014;59:244–251.
Alsina L, Basteiro MG, de Paz HD, et al. Recurrent invasive pneumococcal disease in children: underlying clinical conditions, and immunological and microbiological characteristics. PLoS One. 2015;10:e0118848.
Mason EO Jr, Wald ER, Tan TQ, et al. Recurrent systemic pneumococcal disease in children. Pediatr Infect Dis J. 2007;26:480–484.
Einarsdöttir HM, Erlendsdóttir H, Kristinsson KGG, et al. Nationwide study of recurrent invasive pneumococcal infections in a population with a low prevalence of human immunodeficiency virus infection. Clin Microbiol Infect. 2005;11:744–749.
Ingels H, Schejbel L, Lundstedt AC, et al. Immunodeficiency among children with recurrent invasive pneumococcal disease. Pediatr Infect Dis J. 2015;34:644–651.
Picard C, Bobby Gaspar H, Al-Herz W, et al. International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38:96–128.
Scheifele D. IMPACT after 17 years: lessons learned about successful networking. Can J Infect Dis Med Microbiol. 2009;20:12–14.
Scheifele DW, Halperin SA; CPS/Health Canada, Immunization Monitoring Program, Active (IMPACT). Immunization Monitoring Program, Active: a model of active surveillance of vaccine safety. Semin Pediatr Infect Dis. 2003;14:213–219.
Austrian R. The quellung reaction, a neglected microbiologic technique. Mt Sinai J Med. 1976;43:699–709.
National Advisory Committee on Immunization. Update on pediatric invasive pneumococcal disease and recommended use of conjugate pneumococcal vaccines. Canada Commun Dis Rep. 2010;36:1–30.
Wu S, Guo X, Xu Z, et al. Early clinical predictors for the prognosis of invasive pneumococcal disease. BMC Infect Dis. 2020;20:1–7.
King MD, Whitney CG, Parekh F, et al.; Active Bacterial Core Surveillance Team/Emerging Infections Program Network. Recurrent invasive pneumococcal disease: a population-based assessment. Clin Infect Dis. 2003;37:1029–1036.
Ingels H, Lambertsen L, Harboe ZB, et al. Recurrent invasive pneumococcal disease in children: epidemiological, microbiological, and clinical aspects from a Danish 33-year nationwide survey (1980–2013). Scand J Infect Dis. 2014;46:265–271.
Malo JA, Ware RS, Lambert SB. Estimating the risk of recurrent invasive pneumococcal disease in Australia, 1991–2016. Vaccine. 2021;39:5748–5756.
Mufson MA, Hao JB, Stanek RJ, et al. Clinical features of patients with recurrent invasive Streptococcus pneumoniae disease. Am J Med Sci. 2012;343:303–309.
Butters C, Phuong LK, Cole T, et al. Prevalence of immunodeficiency in children with invasive pneumococcal disease in the pneumococcal vaccine era: a systematic review. JAMA Pediatr. 2019;173:1084–1094.
Bettinger JA, Scheifele DW, Kellner JD, et al. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000–2007. Vaccine. 2010;28:2130–2136.
Sanz JC, Rodríguez-Avial I, Ríos E, et al. Recurrent pneumococcal invasive disease in the region of Madrid during a five-year period. Infection. 2014;42:475–483.